O n July 2, the U.S. Food and Drug Administration (FDA) approved a new drug for treating Alzheimer’s disease. Donanemab, or Kisunla, is the third drug approved to target one of the causes of ...

Donanemab patient: ‘The drug kept me feeling normal, but i’m scared about what happens next’ - Peter Almond finished a trial for Donanemab in September having been on the drug for three years ...

Donanemab and another new drug for Alzheimer’s called Lecanemab have been billed as a huge step forward in research. Stay up to date with notifications from The Independent.

Given this, donanemab is certainly not a “wonder” drug or a “miracle” drug, and describing it as such may give false hope to vulnerable people with dementia and their family carers.

Donanemab can slow the progression of Alzheimer’s disease. But what is the drug and how does it work? Here your questions on the latest development in Alzheimer’s research are answered. The ...

Donanemab is only for use in the early stages of Alzheimer’s disease. And for now at least, it comes with a hefty price tag. The TGA has approved donanemab for Alzheimer’s disease.

This trial may also help answer the niggling question of whether continued donanemab treatment after plaque clearance would be beneficial. Alexander did not discuss what type of small molecule might ...

Donanemab patient: ‘The drug kept me feeling normal, but i’m scared about what happens next’ Peter Almond finished a trial for Donanemab in September having been on the drug for three years ...

The drug contains an antibody that aims to slow the progression of the incurable Alzheimer’s disease. It operates by eliminating the buildup of amyloid protein plaque in the brain.

This week, Australia’s Therapeutic Goods Administration (TGA) approved a drug called donanemab for people in the early stages of Alzheimer’s disease. Donanemab has previously been approved in ...